Systemic antibody response to nano-size calcium phospate biocompatible adjuvant adsorbed HEV-71 killed vaccine.
- Author:
Mohamed Ibrahim SAEED
1
;
Abd Rahaman OMAR
;
Mohd Zobir HUSSEIN
;
Isam Mohamed ELKHIDIR
;
Zamberi SEKAWI
Author Information
- Publication Type:Original Article
- Keywords: Human enterovirus 71; Calcium phosphate; Adjuvanted vaccine; Nanoparticles; Intradermal injections
- MeSH: Animals; Antibody Formation*; Asian Continental Ancestry Group; Calcium*; Communicable Diseases; Enterovirus A, Human; Humans; Immunization; Immunoglobulin G; Injections, Intradermal; Nanoparticles; Particle Size; Rabbits; Vaccines
- From:Clinical and Experimental Vaccine Research 2015;4(1):88-98
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Since 1980s, human enterovirus-71 virus (HEV-71) is one of the common infectious disease in Asian Pacific region since late 1970s without effective commercial antiviral or protective vaccine is unavailable yet. The work examines the role of vaccine adjuvant particle size and the route of administration on postvaccination antibody response towards HEV-71 vaccine adsorbed to calcium phosphate (CaP) adjuvant. MATERIALS AND METHODS: First, CaP nano-particles were compared to a commercial micro-size and vaccine alone. Secondly, intradermal reduced dosage was compared to the conventional intramuscular immunization. Killed HEV-71 vaccines adsorbed to CaP nano-size (73 nm) and commercial one of micro-size (1.7 microm) were administered through intradermal, intramuscular, rabbits received vaccine alone and unvaccinated animals. RESULTS: CaP nano-particles adsorbed HEV-71 vaccine displayed higher antibody than the micro-size or unadsorbed vaccine alone, through both parenteral immunization routes. Moreover, the intradermal route (0.5 microg/mL) of 0.1-mL volume per vaccine dose induced equal IgG antibody level to 1.0-mL intramuscular route (0.5 microg/mL). CONCLUSION: The intradermal vaccine adsorbed CaP nano-adjuvant showed safer and significant antibody response after one-tenth reduced dose quantity (0.5 microg/mL) of only 0.1-mL volume as the most suitable protective, cost effective and affordable formulation not only for HEV-71; but also for developing further effective vaccines toward other human pathogens.
